Dr Tina Bianco-Miotto
Biography/ Background
EDUCATION
1993-1996 Bachelor of Science, The University of Adelaide, SA, Australia
1997 Bachelor of Health Sciences (Honours), The University of Adelaide, SA, Australia
1998-2002 Doctor of Philosophy, The University of Adelaide, SA, Australia
PAST APPOINTMENTS
2002-2003 Research Officer & Visiting Research Fellow, Department of Surgery, Royal Adelaide Hospital & The University of Adelaide
2003-2004 Postdoctoral Fellow, Discipline of Medicine, The University of Adelaide
2005-2009 NHMRC Peter Doherty Fellow, Discipline of Medicine, The University of Adelaide
PRESENT APPOINTMENT
2009- W Bruce Hall Cancer Research Fellow, Cancer Council SA, The University of Adelaide
Publications
1. Chiam K, Ryan NK, Ricciardelli, Day TK, Buchanan G, Ochnik AM, Murti K, Australian Prostate Cancer BioResource, Butler LM, Tilley WD, Bianco-Miotto T. Characterization of the Prostate Cancer Susceptibility Gene KLF6 in Human and Mouse Prostate Cancers. Prostate, May 2012. Accepted with minor revisions.
2. Bianco-Miotto T. Epigenetic Biomarker. In: Encyclopedia of Cancer. Schwab M (Ed), Springer, 2012.
3. Chiam K, Ricciardelli C, Bianco-Miotto T. Epigenetic Biomarkers in Prostate Cancer: Current and Future Uses. Cancer Lett. 2012 Mar 3. [Epub ahead of print]
4. Thompson VC, Day TK, Bianco-Miotto T, Selth LA, Han G, Thomas M, Buchanan G, Scher HI, the Australian Prostate Cancer BioResource, Greenberg NM, Butler LM, Tilley WD. A gene signature identified using a mouse model of androgen receptor-dependent prostate cancer predicts biochemical relapse in human disease. Int J Cancer. 2011 Sep 7. doi: 10.1002/ijc.26414. [Epub ahead of print]
5. Chiam K, Centenera MM, Butler LM, Tilley WD, Bianco-Miotto T. GSTP1 DNA methylation and expression status is indicative of 5-aza-2'-deoxycytidine efficacy in human prostate cancer cells. PLoS One. 2011. 6(9):e25634.
6. Buchanan G, Need EF, Barrett JM, Bianco-Miotto T, Thompson VC, Butler LM, Marshall VR, Tilley WD, Coetzee GA. Corepressor effect on androgen receptor activity varies with the length of the CAG encoded polyglutamine repeat and is dependent on receptor/corepressor ratio in prostate cancer cells. Mol Cell Endocrinol. 2011. 342:20-31.
7. Bianco-Miotto T, Chiam K, Buchanan G, Jindal S, Day TK, Thomas M, Pickering MA, O'Loughlin M, Ryan NK, Raymond WA, Horvath LG, Kench JG, Stricker PD, Marshall VR, Sutherland RL, Henshall SM, Gerald WL, Scher HI, Risbridger GP, Clements JA, Butler LM, Horsfall DJ, Tilley WD, Ricciardelli C and the Australian Prostate Cancer BioResource. Global levels of the histone modification H3K18Ac and a novel epigenetic gene signature predict prostate cancer progression. Cancer Epidemiol Biomarkers Prev. 2010. 19:2611-22.
8. Bianco-Miotto T*, Ricciardelli C*, Jindal S, Dodd TJ, Cohen PA, Marshall VR, Sutherland PD, Samaratunga H, Kench J, Dong Y, Wang H, Clements JA, Risbridger GP, Tilley WD, Horsfall DJ, and the Australian Prostate Cancer BioResource. Comparative biomarker expression and RNA integrity in biospecimens derived from radical retropubic and robot assisted laparoscopic prostatectomies. (*Joint first authors). Cancer Epidemiol Biomarkers Prev. 2010. 19:1755-65.
9. Peters AA, Buchanan G, Ricciardelli C, Bianco-Miotto T, Centenera MM, Harris JM, Jindal S, Segara D, Jia L, Moore NL, Henshall SM, Coetzee GA, Sutherland RL, Butler LM, Tilley WD. Androgen receptor inhibits genomic activity of estrogen receptor-alpha and is prognostic for breast cancer outcome. Cancer Res. 2009. 69:6131-40.
10. Buchanan G, Need EF, Bianco-Miotto T, Greenberg NM, Scher HI, Centenera MM, Butler LM, Robins DM, Tilley WD. Insights from AR gene mutations. In: Androgen Action in Prostate Cancer. Tindall DJ & Mohler JL (Eds). Springer, New York, pp207-240, 2009.
11. Bianco-Miotto T, Hussey DJ, Day TK, O-Keefe DS, Dobrovic A. DNA methylation of the ABO promoter underlies loss of ABO allelic expression in a significant proportion of leukemic patients. PLoS One. 2009. 4(3):e4788.
12. Chiam K, Tilley WD, Butler LM, Bianco-Miotto T. The dynamic and static modification of the epigenome by hormones: a role in the developmental origin of hormone related cancers. Biochim Biophys Acta - Reviews on Cancer. 2009. 1795: 104-109.
13. Cops EJ, Bianco-Miotto T, Moore NL, Clarke CL, Birrell SN, Butler LM, Tilley WD. Antiproliferative actions of the synthetic androgen, mibolerone, in breast cancer cells are mediated by both androgen and progesterone receptors. J Steroid Biochem Mol Biol. 2008. 110:236-43.
14. Marrocco DL, Tilley WD, Bianco-Miotto T, Evdokiou A, Scher HI, Rifkind RA, Marks PA, Richon VM, Butler LM. Suberoylanilide hydroxamic acid (SAHA; vorinostat) represses androgen receptor expression and acts synergistically with an androgen receptor antagonist to inhibit prostate cancer cell proliferation. Mol Cancer Ther. 2007. 6:51-60.
15. Buchanan G, Birrell SN, Peters AA, Bianco-Miotto T, Ramsay K, Cops EJ, Yang M, Harris JM, Simila HA, Moore NL, Bentel JM, Ricciardelli C, Horsfall DJ, Butler LM, Tilley WD. Decreased androgen receptor levels and receptor function in breast cancer contribute to the failure of response to medroxyprogesterone acetate. Cancer Res. 2005. 65:8487-96.
16. Bianco-Miotto T*, Smith E*, Drew P, Watson D. Method for optimizing methylation-specific PCR. BioTechniques. 2003. 35:32-33. (*Joint first authors).
17. Dobrovic A, Bianco T, Tan LW, Sanders T, Hussey D. Screening for and analysis of methylation differences using methylation-sensitive single-strand conformation analysis. Methods. 2002. 27:134-8.
18. Tan LW, Bianco T, Dobrovic A. Variable promoter region CpG island methylation of the putative tumor suppressor gene Connexin 26 in breast cancer. Carcinogenesis. 2002. 23:231-6.
19. Bianco T, Farmer BJ, Sage RE, Dobrovic A. Loss of red cell A, B, and H antigens is frequent in myeloid malignancies. Blood. 2001. 97:3633-39.
20. Bianco T, Chenevix-Trench G, Walsh DC, Cooper JE, Dobrovic A. Tumour-specific distribution of BRCA1 promoter region methylation supports a pathogenetic role in breast and ovarian cancer. Carcinogenesis. 2000. 21:147-51.
21. Butler LM, Dobrovic A, Bianco T, Cowled PA. Promoter region methylation does not account for the frequent loss of expression of the Fas gene in colorectal carcinoma. Br J Cancer. 2000. 82:131-5.
22. Bianco T, Hussey D, Dobrovic A. Methylation-sensitive, single-strand conformation analysis (MS-SSCA): A rapid method to screen for and analyze methylation. Hum Mutat. 1999. 14:289-93.
Entry last updated: Tuesday, 22 May 2012